About this item:

55 Views | 23 Downloads

Author Notes:

Deepak L. Bhatt, 75 Francis St, Boston, MA 02115. Email: dlbhattmd@post.harvard.edu

The authors would like to thank the investigators, the study coordinators, and especially the patients who participated in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial).



  • eicosapentaenoic acid
  • heart failure
  • prevention

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT


Journal Title:

Journal of the American Heart Association


Volume 11, Number 7


Type of Work:

Article | Final Publisher PDF


Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease. Studies of atherothrombotic treatments in this population have been disappointing to date. Icosapent ethyl reduced the risk of atherosclerotic cardiovascular disease among a broad array of statin‐treated patients at elevated risk for atherosclerotic cardiovascular disease. Whether the treatment benefits of icosapent ethyl are consistent among those with HF is unknown.

Copyright information:

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote